Learn More
PURPOSE Sunitinib has demonstrated antitumor activity in metastatic renal cell carcinoma (mRCC) when given at 50 mg/d on a 4-weeks-on 2-weeks-off regimen. Herein, we report results of an open-label,(More)
BACKGROUND Apalutamide is a potent androgen receptor (AR) antagonist that targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene(More)
BACKGROUND This phase 1/2 study assessed sunitinib combined with docetaxel (Taxotere) and prednisone in chemotherapy-naive metastatic, castration-resistant prostate cancer (mCRPC) patients. (More)
4515 Background: Options for treatment of men with mCRPC after progression on docetaxel-based chemotherapy are limited. SU is a multitargeted inhibitor of VEGFR and PDGFR that showed antitumor(More)